Effect of phytoneering remedy BNO 2103 on the course of experimental exudative inflammation caused by different phlogogens

Abstract

Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a trending tendency to pay more attention to herbal medicines, their empirical application and scientific study. The aim of this research is to study anti-inflammatory properties of standardized herbal composition BNO 2103 in a model of paw inflammation in rats caused by different phlogogens to justify the use of it in the treatment of chronic kidney disease (CKD). Materials and methods. The experimental study was performed using 90 male white outbreed rats weighing 150–200 g, which were divided into 3 series of 30 animals each, each series included 3 groups. Inflammation of the paw was induced by subplantar administration of phlogogens – zymosan, histamine and serotonin. The study agent and the reference drug, diclofenac sodium, were administered intragastrically (i. g.) once. Edema was observed and recorded, and anti-inflammatory activity (AIA) was assessed in 0.5, 1.0, 2.0, 3.0 and 6.0 hours after phlogogen injection. Results. BNO 2103 showed a remarkable anti-exudative effect in the model of zymosan and histamine edema, being significantly superior to diclofenac sodium. In the serotonin edema model, BNO 2103 was significantly superior to the comparator by the endpoints, showing the moderate but prolonged anti-exudative effect. Conclusions. BNO 2103 has the significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin), mainly acting on the lipoxygenase pathway of arachidonic acid conversion, which is most likely due to the presence of flavonoids. This allows us to consider BNO 2103 as a promising drug for the treatment of CKD.